乌龙制药 URGN 深 沪
等待开盘 03-26 09:30:00 美东时间
18.12
+0.460
+2.60%
华盛通- 最 高18.37
- 今 开17.69
- 成交量 34.69万股
- 最 低 17.69
- 昨 收 17.66
- 总市值 8.82亿
- 52周最高 30.00
- 市盈率 静 --
- 换手率 0.71%
- 52周最低 3.42
- 委 比 30.92%
- 总股本 4868.23万
- 历史最高 69.568
- 量 比 0.51
- 振 幅 3.85%
- 历史最低 3.42
- 每 手 1
- 风险率 5.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
A survey of more than 1,100 bladder cancer patients reveals that nearly 80% experience fear of recurrence, rising to over 90% among those under 50. Many patients undergo five or more cystoscopies, with some enduring more than 15 procedures. UroGen Pharma and BCAN highlight the chronic nature of bladder cancer, emphasizing the need for treatment discussions that address long-term quality of life and emotional burden. The report underscores the cum...
03-13 12:00
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. granted 11 new employees inducement restricted stock units (RSUs) to support the commercialization of JELMYTO® and ZUSDUR™ and advance its pipeline. Up to 51,200 shares are issuable upon vesting over three years, contingent on continued employment.
03-06 21:10
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
UroGen Pharma: Q4 Earnings Insights
The Q4 earnings report for UroGen Pharma (NASDAQ:URGN) was released on Monday, ...
03-02 21:02
UroGen Pharma Enters Into Agreement With Funds Managed By Pharmakon Advisors To Revise Terms Of Loan Agreement Entered Into In March 2024
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030$200 million funded at closing to refinance the existing $125 million debt facility
03-02 20:57
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
UroGen Pharma Earnings Preview
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report...
02-28 02:02
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
UroGen Pharma Ltd. announce the release of their Q4 and full-year 2025 financial results on March 2, 2026, followed by a live webcast and conference call at 10:00 AM ET. The webcast can be accessed on their Investor Relations website, with a replay available for 30 days. UroGen is a biotech company focused on innovative treatments for urothelial and specialty cancers, utilizing their RTGel® technology.
02-23 13:00
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
